Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

March 1, 2023

NASDAQ US Health Care Biotechnology earnings 69 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us today on this call. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Fady Malik, EVP of R&D, will give updates on omecamtiv mecarbil and aficamten, plus the other drug candidates that make up our early clinical development pipeline. Andrew Callos, EVP and Chief Commercial Officer, will talk more about omecamtiv mecarbil and our specialty cardiology franchise strategy as it relates to aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will share an update on reldesemtiv. Robert Wong, VP and Chief Accounting Officer, will walk through the financials for the quarter just ended, and Ching Jaw, SVP and Chief Financial Officer, will cover our 2023 financial guidance along with corporate development strategies. Then, to wrap up, Robert Blum will offer closing remarks and go over the key milestones we expect in 2023. Please be aware that parts of what we discuss next, including answers to your questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. More details about factors that could make our actual results differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our fourth quarter 2022 financial results filed on Form 8-K and our Form 10-K, both of which were filed today. We have no obligation to update any forward-looking statements after this call. And with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Appreciate that, Diane, and I want to thank everyone for being on today's call. Across our pipeline, the fourth quarter of 2022 saw a lot of productivity, and that momentum carried into the start of this year. Let me start with omecamtiv mecarbil: as of yesterday, a complete response letter came through from the FDA. According to that letter, GALACTIC-HF does not provide persuasive enough evidence to establish substantial proof of effectiveness when it comes to lowering the risk of heart failure events and cardiovascular death among adults who have chronic heart failure with HFrEF, in place of data from a minimum of 2 adequate and well-controlled clinical investigations. The FDA said an additional clinical trial of omecamtiv mecarbil would be necessary to demonstrate substantial evidence of effect for treating HFrEF, with benefits outweighing the risks. Just as we said on this morning's call, we intend to ask for a meeting with the FDA so we can grasp the agency's perspective on the CRL and what might be needed to support a possible approval of omecamtiv mecarbil in the United States; that said, as noted this morning, we do not intend to run another clinical trial of omecamtiv mecarbil, and our attention stays fixed on the aficamten development program. Though this is disappointing, we had prepared for such a possibility. Andrew will go into detail, but in anticipation of this possible result, a significant share of the commercial spending and hiring we had anticipated for 2023 was contingent on omecamtiv mecarbil potentially being approved. Our commercial infrastructure was likewise designed and built so it could pivot toward aficamten, consistent with our specialty cardiovascular franchise strategy. Beyond that, and at the same time, as you will hear more about from my colleagues, during 2023 we will keep working with regulatory authorities to pursue approvals for omecamtiv mecarbil in other countries, and as might lend support to corporate development and business development efforts. As we've said before, we have faith in the science behind omecamtiv mecarbil and in the clinical evidence demonstrated that could potentially help patients with advanced and worsening heart failure; even so, we will not stake the company on omecamtiv mecarbil, and we have a broad pipeline of novel drug candidates directed at muscle biology. Cytokinetics is well positioned to move ahead with aficamten, which stands as our next major opportunity to deliver an important new medicine for patients in need; toward that goal, during the fourth quarter the aficamten development program advanced in both obstructive and nonobstructive HCM. Fady will lay it out, but we're set for a significant year, with data anticipated from Cohort 4 of REDWOOD-HCM in nHCM this coming weekend at the ACC scientific sessions in New Orleans, plus results from the pivotal Phase III trial, SEQUOIA-HCM, later this year in Q4. At the same time, we plan to considerably broaden the aficamten development program by launching 2 new Phase III clinical trials in 2023 — one in OHCM evaluating aficamten as monotherapy, and 1 in nHCM. Regarding reldesemtiv, Stuart is going to give you more detail, but after that initial interim analysis that took place during the prior quarter, enrollment of patients kept going in COURAGE-ALS, and for this ongoing study we anticipate that the data monitoring committee will carry out the second interim analysis during Q2 of this year. Our view is that reldesemtiv has the potential to be a completely novel pharmacology for people with ALS who remain underserved because no muscle-directed therapy exists. As we move into 2023, Cytokinetics continues to stand on a solid financial foundation, with more than 2 years of cash runway ahead, which comes from the strategic, gated way we have built our commercial capabilities, along with our inventive deal-making and disciplined approach to investment spending. Even though we are widening the aficamten clinical development program and also growing and lengthening our early clinical development pipeline—something you will hear additional details about later on today's call—we anticipate that our burn rate for 2023 will fall in a range comparable to 2022. And notwithstanding the disappointing outcome for omecamtiv mecarbil, our mission has not changed, just as it has not for 25 years: to deliver new medicines to patients suffering from diseases involving impaired muscle function, and our belief in that mission is as strong as it has ever been; with that, I will hand the call over to Fady.

Fady Malik

executive
#3

Appreciate that, Robert. Ahead of turning to aficamten, I'd like to say how let down I feel by what happened with omecamtiv mecarbil, and I also want to thank the numerous staff members, study investigators, and patients who gave their time to this development program across the years. We're still engaged with FDA and evaluating what comes next for omecamtiv mecarbil, and meanwhile, during the fourth quarter, the European Medicines Agency gave acceptance to the marketing application for omecamtiv mecarbil. Also, Ji Xing reported that the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China gave acceptance to the NDA submission for omecamtiv mecarbil. As we weigh the program's future within the U.S., we'll keep seeking approvals internationally for omecamtiv mecarbil. Now, on to aficamten. The fourth quarter brought strong headway, with close to 100 clinical trial sites opening for screening; enrollment climbed considerably in SEQUOIA-HCM during the fourth quarter and into early 2023. At this point we've enrolled over 2/3 of the 270 patients we're targeting, and we believe enrollment will wrap up on schedule in the second quarter, with results anticipated in the fourth quarter of the year. Also during the quarter, enrollment finished in Cohort 4 of REDWOOD-HCM. Data from this cohort, covering nonobstructive HCM patients, will be shared in a poster session at the American College of Cardiology Scientific Sessions this coming weekend, which positions us to move into a pivotal Phase III clinical trial for patients with nonobstructive nHCM in the second half of the year. On the REDWOOD-HCM front, we were likewise glad during the quarter to report that full results from cohorts 1 and 2 of REDWOOD-HCM appeared in JACC, detailing its next-in-class profile. Furthermore, we're making additional preparations for our second Phase III clinical trial of aficamten as monotherapy versus metoprolol in patients with obstructive HCM; the trial is named MAPLE-HCM, an acronym for metoprolol versus aficamten in patients with left ventricular outflow tract obstruction on exercise capacity. Enrollment in the trial should start within the second quarter of this year. Before that, though, I want to highlight several key aspects of its design. MAPLE-HCM is a Phase III multicenter, randomized, double-blind, active comparator trial involving patients with symptomatic OHCM and elevated LVOT gradients. Roughly 170 patients are expected to enroll. The primary endpoint is change in peak VO2 assessed by CPET from baseline to week 24. Secondary endpoints take in change in NYHA class, KCCQ, NT-proBNP and measures of structural remodeling. Once enrollment opens, we look forward to sharing further specifics about the trial. Turning to our earlier-stage pipeline, in the fourth quarter we launched a Phase I study of CK-136, our cardiac troponin activator being developed as a potential treatment for patients with HFrEF and other forms of heart failure, including right ventricular failure caused by impaired cardiac contractility. By moving CK-136 forward, we broaden our cardiovascular portfolio, since it could deliver distinct benefits as a possible therapy for these additional kinds of heart failure, working through a different mechanism of action inside the sarcomere. Data from the Phase I trial should be shared in the year's second half. Also, quite recently, we shared preclinical findings on a more recent compound, CK4021586, or CK-586. This is one more cardiac myosin inhibitor. CK-586 works through a mechanism unlike aficamten, and pushing it ahead gives us the chance to investigate how cardiac myosin inhibition might be used therapeutically against particular forms of heart failure with preserved ejection fraction, where hypercontractility could be a factor. We are eager to move this compound into clinical development in this year's first half. Even with the CRL for omecamtiv mecarbil, we still have 3 other cardiovascular drug candidates moving forward in development, with aficamten leading in the pivotal Phase III clinical trial, SEQUOIA-HCM. Our cardiovascular franchise, arising from our sarcomere-directed research, keeps fulfilling the promise of new potential medicines for patients. Having said that, I will hand the call to Andrew so he can discuss omecamtiv mecarbil and our specialty cardiology franchise strategy.

Andrew Callos

executive
#4

Thanks, Fady. Obviously, we're not happy about the complete response letter that came in yesterday, but we had prepared and set aside budget for exactly this kind of situation. As we've said before, a big chunk of the commercial spending and hiring we expected to do in 2023 was contingent on omecamtiv mecarbil getting approved. Now that we've gotten a CRL, we're going to pull back on the commercial spending we would have done if the FDA had given omecamtiv mecarbil the green light. That said, the commercial readiness infrastructure we built was always designed with a cardiovascular franchise strategy in mind, along with the eventual launch of aficamten and other cardiac muscle modulators. More than 90% of the people on our commercial team have duties that aren't exclusively tied to omecamtiv mecarbil. Our parent team is largely the same group that's needed to support aficamten, so we don't intend to cut any jobs. We also won't grow our commercial organization in 2023 — instead, we're shifting our attention to getting ready now for a possible approval and launch of aficamten. This isn't the path we wanted for our company or for patients dealing with heart failure with reduced ejection fraction, but we're nimble, and we'll pivot and execute on this scenario as planned. During Q4, we kept up commercial work tied to aficamten. In the last quarter, we finished an initial go-to-market strategy for aficamten and moved our commercial readiness plans forward. We're inside the window where a great deal of work has to get done to prepare for possible global launches of aficamten across potentially multiple indications. Cardiac myosin inhibition is showing it matters for treating patients with OHCM, and we believe that will drive Cytokinetics to become a global specialty cardiovascular company, with aficamten leading the way and making our planning and execution in both 2023 and 2024 essential. With that, I'll hand the call to Stuart for an update on reldesemtiv.

Stuart Kupfer

executive
#5

Appreciate that, Andrew. Turning to the neuromuscular area, reldesemtiv is still a major late-stage initiative for us. Throughout Q4, we kept moving forward with enrolling patients in COURAGE-ALS, and as of today we've got more than 450 individuals signed up, which represents over three-quarters of the enrollment goal we set. Enrollment should wrap up during Q2 of 2023, with results coming in 2024. Also in that quarter, we shared news that COURAGE-ALS would go on after the initial futility interim analysis performed by the Data Monitoring Committee, which looked at unblinded trial data. A second interim analysis is anticipated in Q2, and that one will evaluate futility too, plus the possibility of a fixed bump in the overall sample size aimed at boosting the trial's statistical power. Additionally, in Q4 of 2022, we kept enrolling people who finished COURAGE-ALS into COURAGE-ALS OLE, our open-label extension, and we moved forward on plans for a managed access program so reldesemtiv can reach patients who've completed any prior ALS study of ours, such as VITALITY-ALS, the Phase III trial of tirasemtiv, and FORTITUDE-ALS, the Phase II trial of reldesemtiv. Lastly, near the end of last year, we were happy to share data at the 33rd International Symposium on ALS/MND drawn from a FORTITUDE-ALS analysis, which demonstrated that a patient's predicted survival risk score had a strong correlation with ALSFRS-R decline, and it hints that the inclusion criteria chosen for COURAGE-ALS should achieve the desired effect of enriching for participants whose disease progresses faster, while reducing—though not eliminating—those whose disease progresses more slowly. With that said, I'll hand things over to Robert Wang.

Robert Wong

executive
#6

Thank you, Stuart. As we closed out the fourth quarter, our cash and investments stood at roughly $830 million. During Q4 2022, the bulk of our revenue came from Astellas, which is helping to fund COURAGE-ALS. R&D spending for the fourth quarter of 2022 rose to $75 million, compared with $43.5 million in the same period of 2021, largely driven by greater outlays for clinical development work on SEQUOIA-HCM and COURAGE-ALS, as well as for our other cardiac muscle inhibitor and early research programs. G&A costs in Q4 2022 reached $54 million, an increase from $33.8 million in Q4 2021, mainly because of higher spending on outside services tied to preparations for a possible commercial launch of omecamtiv mecarbil, along with growth in personnel-related costs such as stock-based compensation. At this point, Ching will walk us through our financial outlook, 2023 guidance and corporate development strategies.

Ching Jaw

executive
#7

Robert, thank you. We released our 2023 financial guidance today. Revenue is expected by the company to come in at around $5 million, which reflects Astellas reimbursing costs tied to COURAGE-ALS. Beyond that, a $50 million milestone payment should come our way from Royalty Pharma once the pivotal Phase III trial of aficamten in non-obstructive HCM begins. Operating expenses are projected between $420 million and $450 million, while net cash utilization should land at roughly $350 million to $375 million. Based on what we expect for 2023 operating expenses and net cash utilization, our present cash balance of about $830 million equates to over 2 years of forward cash. Since a CRL has been received from the FDA, a substantial portion of the cost we would have incurred for the planned U.S. launch of omecamtiv mecarbil will not be spent, and most of that spending had deliberately been gated on possible FDA approval. As Andrew said earlier, with regard to omecamtiv mecarbil, we had prepared for this kind of scenario and kept our spending disciplined by gating the bulk of that potential commercial outlay to FDA approval. Consequently, a significant majority of our commercial infrastructure is able to be redeployed toward supporting potential global launch planning for aficamten. Turning to other programs and this year's spending, out of the roughly $150 million we anticipate directing to clinical development during 2023, about 60% is going toward the aficamten development program. Just as we've done previously, our aim is to finish 2023 with over 2 years of cash runway. Our cash position remains strong, yet as evidence of our intent to keep multiple levers for accessing capital, we will keep pursuing further business development and corporate development deals during this year; and with that, I'll hand the call back to Robert Blum.

Robert Blum

executive
#8

Thanks, Ching. Things didn't turn out as we'd hoped regarding omecamtiv mecarbil, since we got a CRL from FDA, but even so, 2022 was a year marked by truly significant strides as our company matured and transformed. At Cytokinetics, we know a thing or two about getting past obstacles. And like Andrew mentioned, we anticipated this situation and we're ready to keep our momentum going without missing a beat. As we consider what might come next for omecamtiv mecarbil here in the United States, during 2023 our focus stays on aficamten, which is moving forward in an expanding development program featuring a number of key near-term milestones this year. We're eager to share significant new data coming out of REDWOOD-HCM in both non-obstructive and obstructive HCM this weekend at ACC, and to kick off 2 additional Phase III clinical trials within the aficamten development program. Beyond that, we're looking forward to results from SEQUOIA-HCM later in the year. Over recent years, we've viewed this next-in-class cardiac myosin inhibitor as the main fulcrum for building our commercial business both in the United States and abroad, and the recent FDA action hasn't altered that. Reldesemtiv is another promising late-stage opportunity, and we also intend in the year ahead to grow and push forward our early-stage pipeline to underpin our ongoing corporate development. Our future is still bright, and as ever, we're grateful for our shareholders' support. Now let me go over our upcoming milestones for 2023. On omecamtiv mecarbil, we plan to ask for a meeting with FDA to figure out what might be needed to back a potential approval of omecamtiv mecarbil in the United States. And we plan to talk with EMA about the MAA for treating HFrEF. On aficamten, we plan to share data from cohort 4 of REDWOOD-HCM and data from 48 weeks of treatment with aficamten in FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session this weekend. And we plan to finish patient enrollment in SEQUOIA-HCM in Q2 2023, with results from that trial anticipated in Q4 2023; we plan to start MAPLE-HCM, the second Phase III clinical trial of aficamten, as monotherapy in patients with obstructive HCM in Q2 2023, and we plan to start a Phase III clinical trial of aficamten in nonobstructive HCM in the second half of 2023. Also, we plan to move our U.S. go-to-market strategy for aficamten forward during 2023. On CK-136, we anticipate data from the Phase I study of CK-136 in the second half of 2023; on reldesemtiv, we anticipate the Data Monitoring Committee will carry out the second interim analysis from COURAGE-ALS in Q2 2023. We anticipate finishing patient enrollment in COURAGE-ALS also in Q2 2023, with results anticipated in 2024. And on our preclinical development and ongoing research, we anticipate moving CK-586 into clinical development in the first half of this year; and operator, with that, let's now open up the call to questions, please.

Yasmeen Rahimi

analyst
#9

Regarding what happened with omecamtiv, I feel terrible. So I suppose the single thing I want to ask is for Fady, and it concerns SEQUOIA. Is there a mechanism — when patients experience any kind of ejection fraction decline, or when any safety signal comes up, are you informed? Also, could you share whatever you're able to say about what's being observed while the study remains blinded? After that, I'll get back in line and honor your request of one question each.

Fady Malik

executive
#10

Yasmeen, thank you for raising that. Emerging safety data isn't something I'm really able to discuss. What I can share is what's visible to us, and that is: we aren't seeing ejection fractions handled simply through lowering the dose; those situations are managed via the IWRS system that dispenses drug; and for drug to be dispensed, sites must enter the site red ejection fraction. A cardiologist who isn't on the study team and remains blinded to study treatment performs that step; but the — consequently, no notification reaches us when EFs fall under 50%. Should a person's ejection fraction go under 40%, treatment would have to be terminated, and that would turn into a noted event that we would become privy to. But I'm — we're happy with the way things are progressing, and perhaps that's the best way for me to phrase it.

Joe Pantginis

analyst
#11

I'm just wondering — Robert, earlier today you mentioned it's too soon to get into the back-and-forth details regarding omecamtiv in Japan and what's possible in the EU. I wanted to ask whether you have anything to say about the strategy Ji Xing is pursuing, and whether there's anything that sets it apart?

Robert Blum

executive
#12

Right. I ought to let Ji Xing speak to that themselves, since they're the ones handling the regulatory filing in China. That said, I believe the back-and-forth we had with FDA taught us a thing or two about the best way to situate omecamtiv mecarbil in other markets; and I wouldn't view what transpired with FDA as automatically shutting things down elsewhere, particularly given that our approach has been different. That may be the cleanest way to put it. Our tactics differ once you go beyond the United States.

Jason Zemansky

analyst
#13

I'm curious—when you consider a go-to-market approach for aficamten, do you have any thoughts on how dosing monitoring might realistically be carried out? Would it involve a targeted echocardiogram, or possibly either 4 weeks or 8 weeks—something that could help sidestep the kind of 2-week monitoring possibility that appears in the SEQUOIA Phase III design?

Robert Blum

executive
#14

As you can surely understand, how this drug ultimately gets labeled is going to be shaped by the manner in which it was examined in clinical research, though I'll turn it over to Fady to go into more detail.

Fady Malik

executive
#15

Yeah, so to start with, I'd say echocardiograms can be performed in a pretty targeted way. You really just have to look at two things: the gradient and the ejection fraction. In an echo, we also do plenty of additional views and such, which can take more time. But whether to go that route is genuinely something each site has to figure out for itself. As for what you asked about dosing, let me make this clear: the every-2-week schedule used in SEQUOIA should be understood as the shortest interval allowed for dosing. There's no downside. If a patient or their doctor prefers, there's nothing stopping you from going with a longer gap between doses. What I'd anticipate the label saying is that a minimum of 2 weeks must pass before any change in dosing, and beyond that, the patient and physician can decide how much longer to wait.

Robert Blum

executive
#16

One thing we feel good about is that SEQUOIA is going to help patients reach their target dose quickly and find symptom relief quickly. And I believe that ultimately supports our strategy, which is about discussing how the category could eventually grow given that aficamten may become available. And I think Fady might want to add something.

Fady Malik

executive
#17

One more question from my side. Obviously, these individuals have dealt with their symptoms over an extended period, I'd say. That doesn't really take away from how quickly they'd want their symptoms to improve, in my view. Suppose you could pick between needing weeks or months before getting relief from something you've endured for many years, on the one hand, versus a briefer stretch of time, on the other — why wouldn't patients go with the briefer stretch of time, even if they may have had this disease for many years already? So our view is that the faster titration we used in SEQUOIA, meaning the dosing interval, is something patients would find appealing.

Srikripa Devarakonda

analyst
#18

This is Ishan, filling in for Kripa. Regarding omecamtiv, you've mentioned not wanting to conduct an additional U.S. trial. So I'm curious: how probable is it that you would sell this asset off to a business that either already has a franchise established or possesses the capital? And what would the bar be for you to pursue that?

Robert Blum

executive
#19

Yeah, so many of you have raised that same question, and it's only been 24 hours since we got a disappointing CRL, and the way we might eventually monetize omecamtiv mecarbil isn't something we're prepared to discuss openly at this point. What I can tell you is that selling omecamtiv mecarbil off, allowing a different company to conduct clinical trials, is something we ought to think about. But I believe we have prior experience with other firms doing clinical research on omecamtiv mecarbil, and I don't think that's something we feel strongly confident about when it comes to what's best for science or for patients; so perhaps what we'll do instead centers on partnering omecamtiv mecarbil. And I'd say that's the direction we've already been tilting toward. We've already been quite engaged with other companies that have an appetite to partner on omecamtiv mecarbil. And that, I believe, is more likely to be the thing that actually moves the needle for Cytokinetics.

Carter Gould

analyst
#20

Looking forward to seeing you in New Orleans this weekend. That leads nicely into our question. You've talked before about the nonobstructive data serving as a sort of pilot for expanding into HFrEF. So what's your current thinking on the best starting point for a HFpEF trial using one of the myosin activators, and how does 586 entering the clinic either complicate or support that plan?

Robert Blum

executive
#21

Sure. I'll start, and then I'll pass it to Fady. Still, the fact that we're advancing 586 into the clinic highlights how excited we are about inhibiting myosin in HFpEF patients who have hypercontractile ventricles. What you're observing in nHCM — or rather, what we are observing in nHCM, and what you'll observe on Sunday — we think bodes well for this mechanism in particular HFpEF patients, which can now be investigated using 586 as it progresses; so I'll hand things over to Fady to discuss what we specifically see in nHCM and how that relates to those HFpEF patients.

Fady Malik

executive
#22

Back in 2018, during an R&D Day, we set out this approach: oHCM is where a cardiac myosin inhibitor first gets applied, and it clearly extends to nHCM—yet nHCM also gives you what amounts to a genetic model of a more severe type of heart failure with preserved ejection fraction. That applies to patients whose disease shows up as high ejection fraction along with thickened ventricles. Honestly, in many cases, unless you run genetic testing, telling them apart from nHCM patients is tough. So we view this as a natural next step for the development program, and getting 586 into the clinic lets us potentially deploy a different molecule in heart failure with preserved ejection fraction, perhaps with fewer complications when it comes to making it available to that population over the long term.

Robert Blum

executive
#23

You also raised a question regarding the properties of 586. We aren't able to provide that level of detail at this point, but our belief is that 586 works through a mechanism distinct from the one aficamten uses. Further information on that, along with the reasons and the manner in which it could deliver a possible benefit, will be shared as that program advances.

Tessa Romero

analyst
#24

I have one question from a commercial standpoint. Could you share some insight into what you're learning about the market, and which features of aficamten's developing profile might matter most to doctors working in clinics? Also, which prescribing considerations carry the greatest weight for physicians? And how much does that vary across the market? I'm just wondering whether you're picking up on possible distinctions between different HCP segments in the marketplace.

Robert Blum

executive
#25

Absolutely. I'll turn it over to Andrew to weigh in, but let me say upfront that you won't catch us making any comparative statements about aficamten versus mavacamten; in our view BMS is handling mavacamten well and laying a strong foundation for that compound to perform in a chosen group of oHCM patients, yet we're conducting market research on aficamten and the ways its profile might support broadening the category; and I'll let Andrew go deeper on that.

Andrew Callos

executive
#26

Absolutely. Robert, I appreciate that, and I appreciate the inquiry. The main distinctions we're anticipating—or at minimum, in terms of what sets us apart—truly boil down to healthcare utilization along with how physicians and patients experience things, both when beginning and when continuing aficamten, assuming it receives approval. So consider things such as not needing to be concerned about other medications a patient might take regarding drug-to-drug interactions or fetal toxicity, for instance in a woman of child-bearing years, how many Echos might be needed, what kind of REMS programs exist. So these represent genuine or potentially genuine hurdles and distinctions if 1 product has and demands reduced utilization and fewer resources from healthcare and less monitoring and, in a sense, patient follow-up. So I believe these are becoming genuine matters in the marketplace potentially—or distinctions, rather, not matters. But clearly, we must wait until Phase III and what our data would demonstrate to determine whether we can genuinely differentiate.

Robert Blum

executive
#27

The presence of another cardiac myosin inhibitor within this class—much as we've observed in other treatment areas, such as pulmonary arterial hypertension—opens the door to more patients who otherwise may never get the first-in-class agent. And aficamten was engineered specifically to allow for a wide therapeutic window, with quicker onset and quicker reversibility should that be needed. Because of that, it could help support aficamten's use not merely among particular HCM centers of excellence and particular patients, but also among other patients who could benefit, as prescribed by other cardiologists as well; so in the end, what we're aiming for is to give physicians and patients a choice when it comes to a myosin inhibitor for their patients.

Dane Leone

analyst
#28

Congratulations on the advances as we move toward '23. I have a handful of questions that have recently been on many investors' minds. Could you share your perspective on the conversations with the cardiovascular group at the FDA and just how clear they've been regarding endpoints for pivotal trials in nonobstructive hypertrophic cardiomyopathy? As everyone knows, your competitor is utilizing a KCCQ change from baseline event peak VO2, which shares certain similarities with pivotal trials conducted in obstructive disease. What I'd like to hear is your view on, first, what threshold exists for a clinically meaningful change that the FDA group would consider? And second, whether your own experience points you toward the same approach for designing that pivotal trial. Then one very quick question after that. SEQUOIA enrollment continues. I believe some folks are wondering, how tight do you — does your team believe the timing will be for securing top line data prior to the end of the year?

Robert Blum

executive
#29

I'll take the second portion of your question, then have Fady address the first portion. We have strong confidence that we're approaching the finish of enrollment in SEQUOIA, enough to be confident that data will arrive in Q4. If what you're really asking is whether that means October, November, or December, then I suspect we can't provide the level of precision you'd like, given that enrollment in the study hasn't yet wrapped up. Certain factors come into play once it does wrap up, such as how much time we might require for database lock and what remaining queries could still be pending; naturally, we're cleaning data continuously as it arrives. Still, I believe we can state with confidence: Q4. I doubt I can offer anything more precise at this moment. As for endpoints in a pivotal Phase III trial of nHCM, I expect that when we provide details on that trial, after it gets going, you'll notice certain parallels with the ongoing Phase III trial involving mavacamten, along with some clear differences, since aficamten possesses a distinct profile. But I'll let Fady weigh in on what counts as clinically meaningful concerning a number of these endpoints.

Fady Malik

executive
#30

Okay, so the endpoints that we could potentially use in nHCM, I'd say in many respects, are similar to those we will use in oHCM — things like function and symptoms. Peak VO2 is one of them. KCCQ is another, as is NYHA class, and then secondarily, things like biomarkers that we've measured in the past. So when you think about it conceptually, I don't believe there's a huge gap between the two. Part of the issue, I suppose, could be: which one do you request first? And which one do you zero in on? My view is that each of them carries meaning — possibly meaningful, possibly approvable. KCCQ has previously served as an approvable endpoint in pivotal trials. And clearly, we can see that the BMS design folds that into their primary endpoint, while peak VO2 is what we're employing in SEQUOIA; it's a magnitude — broadly speaking, what people seek are magnitudes of 5 points or more on the KCCQ, which is somewhat arbitrary. My feeling is you need to examine the entire distribution and ask whether it's driven — if you came in under 5, yet you had a considerable number of patients who experienced very large improvements, that's quite meaningful for those patients; and if others don't respond to it as a treatment being provided to improve patient symptoms, they can tell you whether they feel better and whether that treatment ought to continue for them. So those discussions will happen with FDA. In the end, the results will shape how we handle potential talks with FDA regarding expanding a label for — in nHCM.

Robert Blum

executive
#31

What I'm hoping for is that when Sunday comes around, the poster will give you information that sheds light on the way aficamten could be taken up in nHCM. Once more, let me remind you that on Monday morning we'll hold a call with investors and analysts so we can go through those data, since they will have been presented the previous day. That, in turn, will shape how we could — expand upon what a Phase III study design might look like, particularly regarding how long treatment lasts and the timing of end points.

Jason Butler

analyst
#32

I have just one question about the upcoming reldesemtiv interim. Could you provide any further specifics regarding how many patients you're able to add? Is there only a single option? Or do multiple options exist for adding varying numbers of patients? And then, any insight into how much longer adding those extra patients would extend the enrollment time lines?

Robert Blum

executive
#33

Yes. I'm going to have Stuart, our Chief Medical Officer, weigh in, but let me note that we have not disclosed the specific number of patients that might be added. It is one number, though perhaps he can address how we plan to handle that.

Stuart Kupfer

executive
#34

Appreciate that, Jason. That's a solid question. The way it's set up, there's a predetermined patient count, and that count would be increased based on whatever conditional power the Data Monitoring Committee sees. Basically, the design works that way so that the size of the change in ALSFRS-R stays hidden. So, in essence, it comes down to two possibilities: the trial gets upsized, or it doesn't. As for how long enrollment would keep going, my sense is that's a topic better addressed if and when the Data Monitoring Committee puts forward its best recommendation. That said, things are moving along quite nicely with enrollment in COURAGE-ALS, and even in the event of an upsizing, we don't anticipate any significant hold-up in getting enrollment finished.

Robert Blum

executive
#35

I might just add a bit more detail there. Let me have Fady share his thoughts on the way the Data Monitoring Committee is receiving its direction.

Fady Malik

executive
#36

Right, so the interim look, I'd say, relies on something referred to as a promising zone design. That design basically exists to steer clear of what I'd call the near miss situation. You've settled on a treatment effect, and then you build the study's power around that figure. As the trial moves along, the effect might turn out bigger than the figure you settled on, and that's obviously a favorable spot to be in. It might also come in somewhat below what you'd assumed. And should it be small enough — even if it's still positive and carries clinical meaning — your power may no longer be sufficient to feel confident the study finishes positive. So this is a single adjustment, made once, that the Data Monitoring Committee is able to apply to a fixed size, fixed increment, and doing so would raise the study's power. Then there's the other possibility: the study might halt early for futility too, in the event it appeared you truly lacked any power to detect a treatment benefit. That, in high-level terms, is how I'd characterize the interim analysis.

Robert Blum

executive
#37

A lot of those represent things that could happen — not necessarily things we think will happen — yet we felt laying them out was worthwhile. There's what you might call an adaptive aspect to how COURAGE-ALS was designed and is being run, since we see it as our duty given that this could become the first therapy in ALS directed at muscle. So before long we'll find out which direction we're headed; and in all likelihood, our expectation is that enrollment will finish in Q2 without the trial either halting ahead of schedule or being expanded.

Charles Duncan

analyst
#38

I'd also like to step away from the afi script and pose a follow-up about reldesemtiv. My apologies in advance — this likely has 3 parts. First, concerning that fixed bump in sample size, might you offer additional detail? Would you characterize it as 10% or 25%? Second, regarding the OLE that's underway, do you have any sense of rollover and persistence, and has Relyvrio had an effect on that? And third, returning to Relyvrio, is it in certain respects altering or influencing which kinds of patients wish to enroll in COURAGE-ALS?

Robert Blum

executive
#39

I'll hand things over to Stuart for these questions, plus anything Fady would like to add. We aren't commenting on how many patients could be added. But as for your question — whether it's 10% more, 25% more — let me simply say it isn't so many additional that we don't anticipate the study could still finish enrollment this year, and so we'd still anticipate results next year, if that's useful to you. That narrows it down; now I'll go to Stuart, perhaps to address the remaining 2 questions.

Stuart Kupfer

executive
#40

Charles, thanks for those questions. Regarding the open-label extension, I believe we can state that the majority of patients are transitioning into the extension. So that trial is progressing well. The effect of Relyvrio has, unsurprisingly, had some influence when it comes to enrollment in North America. However, a substantial share of patients are enrolling in Europe and Australia too. So it truly hasn't made a meaningful difference regarding enrollment in the study; and moreover, since this is now an approved treatment in North America, we are permitting patients to enter the trial even if they are receiving Relyvrio. So any approved therapy is allowed as background therapy in COURAGE-ALS.

Charles Duncan

analyst
#41

That's intriguing; and then the final item regarding enrollment that's being permitted. Is that what you just mentioned?

Fady Malik

executive
#42

Correct; they can enroll in the study if they're taking Relyvrio. That is by — added by amendment; it is comparable to we permit patients on deravone or patients on riluzole to take part.

Justin Kim

analyst
#43

So I think we went over a great deal of territory this morning regarding the pipeline, but perhaps just one point of clarification about the second MAPLE study for aficamten oHCM. I'm just curious what kinds of blocking and tackling are still left to do prior to getting that study underway, and whether it's fair to expect it to begin once enrollment for SEQUOIA has wrapped up?

Fady Malik

executive
#44

Yes, I can address that. Thank you for asking. As we've mentioned previously, this is a complex study to get going when you consider drug supply and such. We're handling packaging, labeling, and manufacturing for 4 distinct supplies: an aficamten, a placebo for aficamten, the metoprolol, and metoprolol for afi — a placebo for metoprolol. So the supply needed for this study is somewhat more involved than what was required for some of our other studies; that's one of those pieces of blocking and tackling we're dealing with; meanwhile, we're kicking off startup activities at sites, which encompass IRB submissions, contracts, and negotiations, all of that kind of thing. And as you pointed out, SEQUOIA is still enrolling, and our preference, clearly, is to avoid competing against ourselves. So there's some load management going on here. And I believe we'll see the study begin around the same time frame as when we see SEQUOIA winding down its enrollment.

Salim Syed

analyst
#45

One thing from me regarding SEQUOIA, I suppose. As people begin shifting how they assess this trial, is there any data whatsoever that Cytokinetics holds on peak VO2 change for aficamten, even if it comes from the OLE? Or does the 1.5 powering for peak VO2 changes here derive from what EXPLORER showed? And keep in mind that was 1.4, and the thinking is aficamten is simply the superior product. Tied quickly to that, will you in fact provide the baseline peak VO2 before the read out, so we're able to handicap the trial?

Robert Blum

executive
#46

Those are good questions. I'll have Fady respond to them.

Fady Malik

executive
#47

Salim, you're likely aware that we haven't disclosed this, and neither the REDWOOD nor FOREST study designs incorporate exercise testing or peak VO2 testing. As a result, we simply don't have any direct data from that kind of assessment with aficamten. Regarding 1.5 versus 1.4, that was essentially a choice on our part to use a round figure, and the statistical power was determined such that we'd have more than 90% power to hit that target. When you look at the raw count of patients enrolled, SEQUOIA is a bit bigger than EXPLORER was, and the p-value for peak VO2 at 1.4 came in below 0.01. That means we ought to be quite adequately powered to detect a gain of 1.5, of 1.4, or even as low as 1.0, which I'd argue reflects, in certain respects, what's regarded as clinically meaningful when it comes to peak VO2. That's genuinely all I'm able to share on that point right now. I believe we have a solid proof of concept demonstrating how a cardiac myosin inhibitor can influence that endpoint. Consequently, this helps reduce the risk, so to speak, attached to the trial's primary endpoint.

Salim Syed

analyst
#48

Do you figure you'll give us that baseline at some stage? Or...

Fady Malik

executive
#49

Most likely just ahead of when you get the primary outcome. But no, my sense is that we won't be handing over those baseline characteristics before the study gets presented.

Serge Belanger

analyst
#50

I have a couple of things about the aficamten Phase III program. The first is about enrollment. It seems roughly 14 to 15 months will be needed to get the 270 patients into the SEQUOIA trial. I'm just wondering whether you anticipate a comparable enrollment speed for the MAPLE study and for the other Phase III trial in HCM, since you're able to run 3 Phase III trials at the same time. And then second, regarding the regulatory approach, should we assume that once MAPLE and the nHCM Phase III trial are finished, each will back separate sNDAs?

Robert Blum

executive
#51

Yes. I'll take the second part first. With our registration strategy, SEQUOIA-HCM forms the critical path, and we'll submit on that basis in oHCM before MAPLE wraps up. But one could picture MAPLE becoming the subject of a supplemental NDA after a possible approval. And likewise, the Phase III study in nHCM, yes, to your question, would again amount to a separate submission and could help support a broader label in nHCM. So from a regulatory perspective, all 3 of those stand apart. I should also point out that our capabilities now mean we would expect — unlike with omecamtiv mecarbil, where a substantial time gap exists between a U.S. submission and a European one — that in HCM we're now set up, we believe, to submit more in parallel around the world so we can help support possible approvals, which would then arrive internationally in quicker succession. So I'll now hand it to Fady to take your first question about how long enrollment is expected to take in those second and third Phase III studies.

Fady Malik

executive
#52

Yeah. I believe this is really a matter of how quickly patients are being enrolled, and I think we're going to — these studies differ somewhat. So when it comes to nHCM, the nHCM study isn't truly going after the same individuals that MAPLE or SEQUOIA would bring in, and we probably will be phasing out enrollment in SEQUOIA prior to those 2 studies genuinely getting going with regard to enrollment; so as far as enrolling at the same time, MAPLE and nHCM aren't in competition with one another. The patient group in MAPLE is somewhat more adaptable, so to speak, regarding who can be brought in. And so it could support, I'd say, ongoing enrollment at the speed that we've witnessed in SEQUOIA. And I think it's a bit too soon — I mean, we've brought the nHCM cohort into REDWOOD fairly quickly, and I'm hopeful we can accomplish that in a Phase III trial too. Hopefully, that addresses your question.

Madhu Kumar

analyst
#53

So, sort of continuing from MAPLE-HCM, I'm interested in how we ought to view this study and what kind of clinical effect and usefulness aficamten could have if it works out. Which sort of untapped area within obstructive HCM does this drug — does this study specifically fill? And then, sort of going back to a few earlier data points from last year regarding drug withdrawal, what's your thinking on that going forward, and on the possible notion of aficamten as monotherapy plus taking away other treatments inside the sort of formal clinical trial context?

Robert Blum

executive
#54

Yes. So, what you're asking touches on the clinical profile as well as the commercial profile; and perhaps Fady could begin discussing what value there might be in showing effects of aficamten compared with metoprolol, but then Andrew ought to weigh in too.

Fady Malik

executive
#55

Our investigators and steering committee members are genuinely enthusiastic about the MAPLE-HCM study. In their view, it addresses a crucial question: obtaining data — and the supporting evidence, so to speak — for aficamten when used as first-line therapy. What we really need to know is what advantages beta blockers provide when given alone. Generally speaking, you do observe decreases in gradient and easing of symptoms, yet essentially no gain in exercise capacity; thus the comparison in a head-to-head trial against aficamten could eventually lend support, at least scientifically, to adopting it as first-line treatment. Another aspect involves examining structural remodeling under beta blockade versus what happens with cardiac myosin inhibition. Although that isn't an endpoint likely to win approval, it still highlights how these 2 drugs might alter the disease's trajectory differently. So in my view, this information will prove extremely useful to the HCM community regarding how to position this mechanism of action both within their practices and within their guidelines.

Andrew Callos

executive
#56

One more point I might make, looking at it commercially: patients and doctors definitely tell us they'd rather take one therapy instead of two if that were possible, though they aren't willing to make that switch absent proof. Such proof doesn't just back up educated use — it may additionally help shape changes to guidelines and influence how payers view which steps must come first before, for instance, aficamten gets covered. Must the patient go through a sequence? Must the patient face a condition of needing more than one therapy? Might this eliminate a stage for a patient? Those are the kinds of places where a trial such as MAPLE might do more to distinguish and educate prescribers along with the payer community.

Robert Blum

executive
#57

It's easy to see why payers would view an advantage over metoprolol as justification for a loftier benchmark when it comes to pricing. That's also something we keep in mind as we consider what a go-to-market approach for aficamten could look like.

Robert Blum

executive
#58

Appreciate you all being here, both for today's call and for the one earlier this morning. Since we've already run past an hour, these closing comments will be short. So let me just put it plainly: yes, we're disappointed about what the FDA did regarding omecamtiv mecarbil. That said, no matter how things shook out, 2023 was always going to be the year we went all in on aficamten — boosting our investment in it and broadening its development program. That isn't to suggest reldesemtiv and our earlier-stage pipeline don't matter too, but I believe we share our shareholders' view that aficamten is a place where returns ought to be reliably greater, and we get that, and that's where our attention will go. When it comes to omecamtiv and each of our dealings with regulators, we won't be giving a play-by-play until we've got something material to share. Rather, expect that during 2023, beginning this weekend, aficamten will be what we discuss far more. On that note, let me wrap up this call. Many thanks for your interest in everything we're doing at Cytokinetics and for all your support — we're eager to keep you updated on how we progress this year.

Operator

operator
#59

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.